FDA Panel Shoots Down Early Approval Request For Experimental Lung-Cancer Treatment

The advisory panel is recommending that the Food and Drug Administration wait for data from a phase 3 clinical trial before deciding on Clovis' rociletinib. In other agency news, an FDA official says long-awaited biotech medicine guidelines are still in the works.

Clovis Oncology Inc. said a U.S. Food and Drug Administration advisory panel voted to recommend against early approval for the biopharmaceutical company’s experimental lung-cancer treatment. Shares fell 5.4% on Tuesday during the regular session and declined a further 3% to $13.81 in recent after-hours trading. It is the latest setback for Clovis whose lung-cancer treatment—called rociletinib—faces competition from a rival drug from AstraZeneca PLC called Tagrisso, which received U.S. regulatory approval earlier in November. (Stynes, 4/12)

The director in charge of FDA’s biotechnology products office said Tuesday the agency continues to work on a long-awaited guidance to inform manufacturers of copycat biotech medicines how to prove similarity to the brand-name drug. (Williams, 4/12)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.

�鶹Ů��

Trump 2.0

Public Health

Audio Reports

Special Reports

More Topics